http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
대장암에 대한 5 - Flurouracil 지속주입 및 Cisplatin ( FP ) 복합화학요법의 치료효과
서철원(Cheol Won Suh),김시영(Si Young Kim),방영주(Yung Ju Bang),김노경(Noe Kyeong Kim),박재갑(Jae Gahb Park),이건욱(Kuhn Uk Lee),홍성국(Sung Kuk Hong),최국진(Kuk Jin Choe),김수태(Soo Tae Kim),하성환(Sung Hwan Ha),박찬일(Chan Il Park) 대한내과학회 1988 대한내과학회지 Vol.35 No.4
N/A Between August 1986 and February 1988, 60 patients with metastatic or recurrent colorectal cancer were treated with a combination chemotherapy consisting of 5-fluorouracil, 1,000 mg/m² iv continuous infusion over 12 hours on Days 1-5 and cisplatin,.60 mg/m² iv on Day 1; cycled every 3 weeks, Among 36 patients with measurable disease, none achieved complete response and 9 (25%) had partial responses, thus this combination chemotherpay regimen showed modest action on the advanced colorectal cancer. The median duration of response was 20 weeks. Median survival was 52 weeks for all patients who could be evaluated for response and/or toxicity; 61 weeks for patients with response, 48 weeks for those with stable disease and 17 weeks for those with progressive disease. In the analysis of the response according to the various pretreatment characteristics of the patients, those without a history of previous anticancer chemotherapy showed response rate of 36% which is better than 7% for those with prior chemotherapy. The patients with metastatic sites in the liver had a response rate of 47%, which is significantly better than 7 96 for those with metastatic site in the lung and 0% for those with any other sites of metastasis. Toxicity was common, but generally mild to moderate and rapidly reversible.
만성 골수성 백혈병 환자의 생존율 및 예후 인자 - 만성기 Ph1 환자의 분석 -
양성현(Sung Hyun Yang),서철원(Cheol Won Suh),방영주(Yung Ju Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),이문호(Mun Ho Lee),김승택(Seung Taik Kim),이홍복(Hong Bock Lee) 대한내과학회 1988 대한내과학회지 Vol.35 No.4
N/A The prognostic significance of different clinical and laboratory findings at the time of diagnosis was anal- yzed among 136 patients with chronic myelogenous leukemia (CML). These patients were collected in the department of internal medicine of Seoul National University Hospital from January 1977 to December 1986. The incidence was not different between both sexes and peak incidence was third decade. The median survival time of all patients from diagnosis was 34.7 months. The cytogenetic study was performed in 110 patients of which 17% were Ph1-negative. These poor prognosis group, showing a shorter survival (14.4 months) than Ph1-positive ones (35.3 months), displayed lower platelet and white blood cell counts and lower percentage of myeloblast in peripheral blood. The prognostic analysis was restricted to the relatively good prognosis group, 85 Ph1-positive patients in chronic phase. From the univariate analysis, patient characteristics associated with shortened survival were age over 50 years old and peripheral basophils over 10%. These two factors were not interrelated. When patients were segregated according to the prognostic factors, it was possible to identify a low-risk group with median survival of 4S months, and a high-risk group with median survival of 1B months.
박인숙,김동섭,최기환,왕소영,임화경,오우용,김소희,강주희,방영주,김주일,Park, In-Sook,Kim, Dong-Seop,Choi, Ki-Hwan,Wang, So-Young,Lim, Hwa-Kyung,Oh, Woo-Young,Kim, So-Hee,Kang, Ju-Hee,Bang, Yung-Jue,Kim, Joo-Il 대한임상약리학회 2002 臨床藥理學會誌 Vol.10 No.2
The enormous cost, intensive time, and constant efforts are required the drug discovery and development of bringing new drug products to the marketplace. The past several years, KFDA approved new drugs developed by local pharmaceutical industries; that is Sunppla, Factive etc. In addition to, investigational new drug application (IND) was established to accelerate new drug development and harmonize with international standards in 2002. At this point of time it is urgent problem to develop ability of reviewing new drug applications (NDAs) scientifically and appropriately to ensure that new drugs are safe and effective. There are many scientific issues embedded in new drug approval process from non-clinical studies to phase 3 clinical trials; 1) sample size, 2) application of end point, 3) statistical method, and etc. However the overall relation between protocols/reports of clinical trials and the characteristics of domestic medical system has fully not been studied. There is also, no references or data for the point to be considered in drug approval process. On this background, the objectives of this study are introduction of guidelines for the requirement for approval or evaluation of safety/efficacy in other countries and presentation how to practice clinical trial for new oncologic products in the present situation of clinical trial. We hope that the guidelines contribute to providing methods of clinical trials and procedures, and evaluating method to develop chemotherapeutic agents.
신기철 ( Ki Chul Shin ),이윤종 ( Yun Jong Lee ),최영주 ( Young Ju Choi ),강성욱 ( Seong Wook Kang ),이은봉 ( Eun Bong Lee ),방영주 ( Yung Jue Bang ),송영욱 ( Yeong Wook Song ) 대한류마티스학회 1999 대한류마티스학회지 Vol.6 No.4
The coexistence of autoimmune and lymphoproliferative disorders has rarely been reported. We report 3 cases of malignant lymphoma associated with systemic lupus erythematosus(SLE). In one case, Hodgkin`s disease and SLE occurred simultaneously. In the other 2 cases, non-Hodgkin`s lymphoma occurred prior to and after development of lupus, respectively. The clinical courses of the patients are described with review of the literature.